Two-year Follow-up of Selective Laser Trabeculoplasty as Initial and Adjunctive Treatment for Ocular Hypertension and Open Angle Glaucoma

Sang Jeong Moon; Eun Su Choi; Jong Il Park; Kyung Hun Lee

doi:10.3341/jkos.2010.51.7.974

Journal List > J Korean Ophthalmol Soc > v.51(7) > 1008863

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Moon, Choi, Park, and Lee: Two-year Follow-up of Selective Laser Trabeculoplasty as Initial and Adjunctive Treatment for Ocular Hypertension and Open Angle Glaucoma

Original Article

J Korean Ophthalmol Soc 2010;51(7):974-980.

Published online: 31 August 2010

DOI: https://doi.org/10.3341/jkos.2010.51.7.974

Two-year Follow-up of Selective Laser Trabeculoplasty as Initial and Adjunctive Treatment for Ocular Hypertension and Open Angle Glaucoma

Sang Jeong Moon, MD, Eun Su Choi, MD, Jong Il Park, MD, Kyung Hun Lee, MD

Sungmo Eye Hospital, Busan, Korea

Address reprint requests to Kyung Hun Lee, MD Sungmo Eye Hospital #1078-7 Woo 2-dong, Haeundae-gu, Busan 612-823, Korea Tel: 82-51-743-0775, Fax: 82-51-743-0776, E-mail: sungmo@sungmo.co.kr

Received 13 April 2009 Accepted 14 May 2010

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

To assess the efficacy and safety of selective laser trabeculoplasty (SLT) as initial and adjunctive treatment for ocular hypertension and open angle glaucoma.

Methods

Twenty-four eyes with ocular hypertension and 63 eyes with open angle glaucoma were treated with a frequency- doubled, Q-switched Nd:YAG laser. Intraocular pressure (IOP) was measured prelaser treatment, one week, one, two, three, six, 12, 18, and 24 months after treatment.

Results

The average pre-laser IOP of 87 eyes was 21.6 mmHg. The mean IOP percent reductions at 1 week, one, two, three, six, 12, 18, and 24 months were 15.3%, 20.0%, 21.3%, 19.6%, 23.4%, 23.4%, 20.5%, and 20.9%, respectively. The IOP percent reductions in the initial treatment group at one, 12, and 24 months were 21.1%, 24.8%, and 22.8% respectively. The IOP percent reductions in the adjunctive treatment group at 1, 12, and 24 months were 19.6%, 22.9%, and 20.2% respectively. There were no differences in IOP percent reduction between the initial treatment group and the adjunctive treatment group.

Conclusions

Selective laser trabeculoplasty has shown reasonable efficacy in lowering IOP over two-year follow-up period as initial and adjunctive treatment for ocular hypertension and open angle glaucoma.

Keywords: Open angle glaucoma, Ocular hypertension, Selective laser trabeculoplasty

References

1. Latina MA, Sibayan SA, Shin DH, et al. Q-switched 532-nm Nd:YAG laser trabeculoplasty (selective laser trabeculoplasty): a multi-center, pilot, clinical study. Ophthalmology. 1998; 105:2082–8.

2. Latina MA, Gulati V. Selective laser trabeculoplasty: stimulating the meshwork to mend its ways. Int Ophthalmol Clin. 2004; 44:93–103.

3. Kim JS, Lee YG, Hong YJ. Q-switched frequency doubled Nd:YAG la-ser trabeculoplasty. J Korean Soc. 1999; 40:2591–6.

4. Suhk HJ, Kook MS. Three year follow up of lasertraebculoplasty using Q-switched frequency doubled Nd:YAG laser. J Korean Soc. 2003; 44:1853–9.

5. Lai JS, Chua JK, Tham CC, Lam DS. Five-year follow-up of selective laser trabeculoplasty in Chinese eyes. Clin Experiment Ophthalmol. 2004; 32:368–72.

6. Weinand FS, Althen F. Long-term clinical results of selective laser trabeculoplasty in the treatment of primary open angle glaucoma. Eur J Ophthalmol. 2006; 16:100–4.

7. Wise JB, Witter SL. Argon laser therapy for open-angle glaucoma. A pilot study. Arch Ophthalmol. 1979; 97:319–22.

8. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. Glaucoma Laser Trial Research Group. Am J Ophthalmol. 1995; 120:718–31.

9. Melamed S, Pei J, Epstein DL. Short-term effect of argon laser trabeculoplasty in monkeys. Arch Ophthalmol. 1985; 103:1546–52.

10. Wise JB. Glaucoma treatment by trabecular tightening with the argon laser. Int Ophthalmol Clin. 1981; 21:69–78.

11. Grayson DK, Camras CB, Podos SM, Lustgarten JS. Long-term reduction of intraocular pressure after repeat argon laser trabeculoplasty. Am J Ophthalmol. 1988; 106:312–21.

12. Richter CU, Shingleton BJ, Bellows AR, et al. Retreatment with argon laser trabeculoplasty. Ophthalmology. 1987; 94:1085–9.

13. Latina MA, Park C. Selective targeting of trabecular meshwork cells: in vitro studies of pulsed and CW laser interactions. Exp Eye Res. 1995; 60:359–71.

14. Latina MA, de Leon JM. Selective laser trabeculoplasty. Ophthalmol Clin North Am. 2005; 18:409–19.

15. Kramer TR, Noecker RJ. Comparison of the morphologic changes after selective laser trabeculoplasty and argon laser trabeculoplasty in human eye bank eyes. Ophthalmology. 2001; 108:773–9.

16. Rozsival P, Kana V, Hovorkova M. Selective laser trabeculoplasty. Ceska Slov Oftalmolo. 2004; 60:267–74.

17. Kim YJ, Moon CS. One – year follow – up of laser trabeculoplasty using Q-switched frequency – doubled Nd:YAG laser of 523 nm wavelength. Ophthalmic Surg Lasers. 2000; 31:394–9.

18. Nagar M, Howes F. Selective laser trabeculoplasty: a new approach to open-angle glaucoma management. American Academy of Ophthalmology Meeting. 2002.

19. Hodge WG, Damji KF, Rock W, et al. Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. Br J Ophthalmol. 2005; 89:1157–60.

20. Martinez-de-la-Casa JM, Garcia-Feijoo J, Castillo A, et al. Selective vs argon laser trabeculoplasty: hypotensive efficacy, anterior chamber inflammation, and postoperative pain. Eye. 2004; 18:498–502.

21. Damji KF, Bovell AM, Hodge WG, et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial. Br J Ophthalmol. 2006; 90:1490–4.

22. Popiela G, Muzyka M, Szelepin L. Use of YAG-Selecta laser and argon laser in the treatment of open angle glaucoma. Klin Oczna. 2000; 102:129–33.

23. Scherer WJ. Effect of topical prostaglandin analog use on outcome following selective laser trabeculoplasty. J Ocul Pharmacol Ther. 2007; 23:503–12.

24. Lanzetta P, Menchini U, Virgili G. Immediate intraocular pressure response to selective laser trabeculoplasty. Br J Ophthalmol. 1999; 83:29–32.

25. Johnson PB, Katz LJ, Rhee DJ. Selective laser trabeculoplasty: pre-dictive value of early intraocular pressure measurements for success at 3 months. Br J Ophthalmol. 2006; 90:741–3.

26. Gracner T, Falez M, Gracner B, Pahor D. [Long-term follow-up of selective laser trabeculoplasty in primary open-angle glaucoma]. Klin Monatsbl Augenheilkd. 2006; 223:743–7.

27. Nagar M, Ogunyomade A, O'Brart DP, et al. A randomised, prospective study comparing selective laser trabeculoplasty with latano-prost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. Br J Ophthalmol. 2005; 89:1413–7.

28. Damji KF, Shah KC, Rock WJ, et al. Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial. Br J Ophthalmol. 1999; 83:718–22.

Figure 1.

Mean intraocular pressure of all groups, initial group, adjunctive group during follow-up.

Figure 2.

Mean intraocular pressure according to the numbers of glaucoma medications

Figure 3.

Mean intraocular pressure of bimatoprost group and latanoprost group.

Table 1.

Pretreatment patient characteristics

Characteristics
Number of patients (eyes)	51 (87)
male	33 (64.7%)
female	18 (35.3%)
Diagnosis
Ocular hypertension	20 (23.0%)
Primary open angle glaucoma	67 (77.0%)
Mean preoperative glaucoma medications	1.14±0.93
0 glaucoma medication	24 (27.6%)
1 glaucoma medication	35 (40.2%)
2 glaucoma medication	20 (23.0%)
3 glaucoma medication	8 (9.2%)

Table 2.

Intraocular pressure (mean± SD) during the follow-up

Time	IOP of initial group (mmHg)	IOP of adjunctive group (mmHg)
Baseline	24.9±2.0	20.3±4.3
1 week	20.6±3.0	17.1±3.7
1 month	20.0±2.6	16.1±3.3
2 months	19.1±3.9	15.8±3.1
3 months	19.4±3.3	16.0±3.0
6 months	18.5±2.5	15.4±2.6
12 months	18.6±2.0	15.3±3.0
18 months	18.9±1.7	15.9±2.9
24 months	19.2±2.0	15.2±2.6

^* Mann-Whitney test.

Table 3.

Mean intraocular pressure reduction during the follow-up

Time	IOP reduction of initial group (%)	IOP reduction of adjunctive group (%)	p-value^*
1 week	16.9±11.9	14.6±12.9	0.78
1 month	21.1±10.5	19.6±11.8	0.91
2 months	23.1±16.7	20.5±14.5	0.62
3 months	21.9±12.3	18.8±15.7	0.69
6 months	25.6±10.8	22.6±12.3	0.59
12 months	24.8±10.1	22.9±14.8	0.73
18 months	23.9±7.7	19.3±15.1	0.26
24 months	22.8±8.0	20.2±13.5	0.71

^* Mann-Whitney test.

Table 4.

Comparison of intraocular pressure reduction according to numbers of glaucoma medication

Time	IOP reduction of 1 medication (%)	IOP reduction of 2 medications (%)	IOP reduction of 3 medications (%)	p-value^*
1 week	15.3±11.3	13.9±15.3	13.5±17.4	0.92
1 month	20.2±11.7	19.2±11.6	18.0±17.4	0.92
2 months	20.0±13.4	20.8±11.3	22.6±20.9	0.88
3 months	15.6±16.6	23.4±13.2	21.2±24.0	0.25
6 months	20.5±14.2	23.9±10.0	28.3±11.0	0.24
12 months	21.0±15.2	23.3±17.7	30.2±17.1	0.37
18 months	19.7±17.3	16.1±17.3	25.2±13.6	0.36
24 months	20.6±14.1	23.2±14.1	10.8±20.0	0.45

^* Kruskal-Wallis test.

Table 5.

Comparision of mean intraouclar pressue reduction of bimatoprost group and latanoprost group

Time	IOP reduction of bimatoprost group (%)	IOP reduction of latanoprost group (%)	p-value^*
1 week	17.3±11.2	13.3±14.4	0.63
1 month	22.5±11.4	17.8±13.2	0.21
2 months	22.2±12.3	19.5±14.3	0.71
3 months	19.9±17.1	19.6±16.9	0.99
6 months	23.3±10.2	21.7±15.3	0.98
12 months	24.1±15.2	22.3±18.4	0.84
18 months	21.0±12.0	19.1±21.1	0.72
24 months	21.2±11.7	20.9±16.8	0.92

^＊ Mann-Whitney test.

TOOLS

Similar articles